Anti-Coagulants - Asia

Asia

The Anti-Coagulants market in Asia is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is estimated to reach US$6.95bn in 2024.
Furthermore, it is anticipated that the market will experience a compound annual growth rate (CAGR 2024-2029) of 7.85%, leading to a market volume of US$10.14bn by 2029.
When compared to other regions globally, United States is expected to generate the most revenue in the Anti-Coagulants market, with an estimated value of US$16,740.00m in 2024.
In the Asian market, Japan has emerged as a leading country in the development and adoption of innovative anti-coagulant therapies.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The use of Anti-Coagulants has been on the rise in Asia in recent years, with a growing number of patients opting for these drugs to prevent blood clots and reduce the risk of stroke.

Customer preferences: The increasing prevalence of lifestyle diseases such as obesity, diabetes, and hypertension has led to a rise in the number of patients suffering from cardiovascular diseases. As a result, there is a growing demand for Anti-Coagulants in Asia, as these drugs are highly effective in preventing blood clots and reducing the risk of stroke. Patients are also increasingly opting for newer and more advanced Anti-Coagulants that have fewer side effects and are more convenient to use.

Trends in the market: Japan is the largest market for Anti-Coagulants in Asia, with a high prevalence of cardiovascular diseases and a rapidly aging population. The market for Anti-Coagulants in Japan is dominated by novel oral anticoagulants (NOACs) such as Apixaban, Rivaroxaban, and Dabigatran, which are more effective and convenient to use than traditional Anti-Coagulants such as Warfarin. In China, the Anti-Coagulants market is growing rapidly, driven by a large patient population and increasing awareness of the benefits of these drugs. The market is dominated by Warfarin, which is cheaper and more widely available than NOACs. However, NOACs are expected to gain market share in the coming years due to their superior efficacy and safety profiles.

Local special circumstances: In India, the Anti-Coagulants market is dominated by Heparin, which is widely used in hospitals for the prevention and treatment of blood clots. However, the market is expected to shift towards NOACs in the coming years, driven by increasing patient awareness and the availability of newer and more advanced drugs. In South Korea, the Anti-Coagulants market is driven by a high prevalence of atrial fibrillation and a growing elderly population. The market is dominated by Warfarin, but NOACs are expected to gain market share in the coming years due to their superior efficacy and safety profiles.

Underlying macroeconomic factors: The Anti-Coagulants market in Asia is expected to continue growing in the coming years, driven by a growing elderly population, increasing prevalence of cardiovascular diseases, and rising patient awareness. The market is also expected to shift towards newer and more advanced drugs such as NOACs, which are more effective and convenient to use than traditional Anti-Coagulants. However, the high cost of these drugs may limit their adoption in some markets, particularly in low- and middle-income countries. Additionally, the regulatory environment in some countries may pose challenges to the entry of new drugs into the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.